Endoplasmic Reticulum-Targeting Natural Compounds: A Novel Frontier in Alleviating Liver Fibrosis Authors: Chengrong Huang, Wei Hu, Jia Qi, Bolun Su, Hongrui Yan, Yi Zhun Zhu Published: 2025 ABSTRACT AbstractLiver fibrosis, a reversible yet critical stage in chronic liver disease progression, poses a significant global health burden with limited therapeutic options. This review comprehensively explores the molecular mechanisms of endoplasmic reticulum (ER) stress and its dual role in both parenchymal and non-parenchymal cells during liver fibrosis, alongside the therapeutic potential of natural compounds that target ER stress to alleviate fibrosis. Emerging evidence underscores ER stress and oxidative stress as pivotal drivers of hepatic fibrogenesis, primarily through activating hepatic stellate cells (HSCs). We systematically summarize a wide array of natural compounds, from polyphenols to terpenoids, that demonstrate potent anti-fibrotic effects by either ameliorating maladaptive ER stress in hepatocytes or selectively inducing pro-apoptotic ER stress in activated HSCs. Despite their promise, the clinical translation of these compounds is hampered by poor bioavailability and non-specific targeting. We highlight the groundbreaking potential of biomimetic nano-delivery systems, such as cell membrane-camouflaged nanoparticles, to overcome these barriers, offering precise targeting and enhanced therapeutic efficacy. Finally, we discuss current challenges and future directions, advocating for interdisciplinary efforts to advance ER stress-targeting strategies from bench to bedside. Introduction Liver fibrosis is a pathological repair process triggered by chronic liver disease, characterized primarily by the excessive accumulation or abnormal distribution of extracellular matrix (ECM) components within the space of Disse.1 Liver fibrosis is typically caused by a various of etiological factor, including viral infections,2 metabolic abnormalities,3 alcohol use disorders,4 cholestasis,5 and autoimmune liver diseases.6 Additionally, long-term use of certain medications such as methotrexate, methyldopa, chlorpromazine, and tolbutamide has also been identified as a contributing factor to the progression of fibrosis.7–9 Without effective intervention, liver fibrosis may advance to cirrhosis or even hepatocellular carcinoma, posing a significant global health burden. According to the most recent Global Burden of Disease data, liver cirrhosis led to over 1.4 million deaths globally in 2021, with the global incidence having increased by 58% between 1990 and 2021, highlighting a growing challenge.10 Currently, treatments targeting the underlying causes, for example antiviral therapies for hepatitis B or C, can partially reverse fibrosis.11,12 Despite advancements in diagnostic techniques and therapeutic strategies, current treatments remain limited in efficacy, underscoring the urgent need for the development of novel anti-fibrotic therapies as a critical medical challenge. Among the complex mechanisms driving liver fibrosis, endoplasmic reticulum (ER) stress has emerged as a pivotal contributor.13 Specifically, disruption of ER function triggers the unfolded protein response (UPR), which is a cellular stress response aimed at restoring ER homeostasis. However, under prolonged stress conditions, chronic ER stress leads to the sustained activation of UPR signaling pathways, ultimately resulting in inflammation, oxidative stress, and apoptosis.14 Notably, these processes play a central role in the activation of HSCs, the primary effector cells responsible for ECM deposition and fibrogenesis.15 Consequently, targeting ER stress has garnered significant attention as a promising therapeutic strategy for liver fibrosis. Natural compounds have gained prominence in drug discovery and development due to their structural diversity, broad biological activities, and favorable safety profiles.16 Unlike synthetic drugs, many natural compounds exhibit lower toxicity and higher biocompatibility, making them attractive candidates for the treatment of chronic diseases. Recent studies have identified several natural compounds, such as curcumol, resveratrol, and chrysophanol, that mitigate ER stress by modulating UPR signaling pathways, thereby inhibiting HSC activation and attenuating fibrosis progression.17,18 These findings not only provide novel insights into the mechanisms of ER stress but also underscore the therapeutic potential of natural compounds in combating liver fibrosis. However, challenges such as poor bioavailability and limited targeting hinder their clinical application. Emerging nano-delivery systems, including liposomes and polymeric nanoparticles, offer promising solutions by enhancing stability, enabling targeted delivery to HSCs, and improving therapeutic efficacy.19 The integration of nanotechnology with natural compounds represents an advanced strategy for precise ER stress modulation in liver fibrosis treatment. This review aims to comprehensively examine the role of ER stress in the pathogenesis of liver fibrosis and explore the therapeutic potential of natural compounds that target ER stress. First, we will elucidate the molecular mechanisms of ER stress and its contribution to liver fibrosis. Next, we will highlight key natural compounds that modulate ER stress and discuss their mechanisms of action. Finally, we will address the limitations of current research and outline future directions to advance this promising field. By providing a thorough overview, this review seeks to offer new perspectives on the treatment of liver fibrosis and to promote the development of natural compounds as viable therapeutic options. ER Stress and UPR The ER is a membranous organelle in eukaryotic cells, extending from the nuclear envelope and consisting of two distinct regions: the rough ER and the smooth ER. The ER is a multifunctional organelle responsible for the synthesis, processing, and transport of proteins and lipids, as well as the regulation of calcium homeostasis and cellular signaling. Under stress conditions such as nutrient deprivation or hypoxia, misfolded or unfolded proteins accumulate within the ER lumen. This accumulation disrupts protein homeostasis, triggering ER stress.20 The UPR responds to ER stress by enhancing protein folding, degrading misfolded proteins via ER-associated protein degradation (ERAD), and reducing new protein synthesis, restoring ER homeostasis and alleviating misfolded protein accumulation.21,22 The biological outcomes of ER stress activation vary depending on its severity: mild ER stress induces the UPR, lowering protein translation levels and reducing the generation of unfolded proteins, while severe ER stress triggers widespread UPR activation, including apoptotic pathways, ultimately leading to cell death.20,23 The classical UPR signaling pathways are initiated by three ER transmembrane proteins: inositol-requiring enzyme 1 (IRE1), activating transcription factor 6 (ATF6), and protein kinase R-like endoplasmic reticulum kinase (PERK). Among these, the 78 kDa glucose-regulated protein (GRP78), also known as immunoglobulin heavy chain-binding protein (BiP), is one of the most extensively studied ER chaperones.24 Under non-stress conditions, GRP78 binds to the luminal domains of these three ER transmembrane sensors. The accumulation of unfolded or misfolded proteins in the ER lumen leads to the dissociation of GRP78 from these sensors, thereby activating the UPR.25 IRE1 Pathway IRE1 is the most evolutionarily conserved ER stress sensor and is a type I transmembrane protein found in the ER of all eukaryotes.26 It contains a serine/threonine protein kinase domain and an RNase domain. When the kinase domain of IRE1α detects misfolded or unfolded proteins, it dissociates from GRP78, dimerizes, and undergoes autophosphorylation, activating its RNase domain.27 The X-box binding protein 1 (XBP1) initially exists in an immature form but is spliced into its mature form (XBP1s) by the endonuclease activity of IRE1α under ER stress conditions. XBP1s then translocates to the nucleus, regulating the expression of genes involved in protein folding and ER-associated protein degradation (ERAD).28 Subsequently, ERAD binds to the cytoplasmic ubiquitin proteasome system, reducing the accumulation of unfolded proteins and restoring ER homeostasis. Additionally, IRE1α activation can lead to mRNA degradation through a process known as regulated IRE1α-dependent decay (RIDD), further reducing the protein load.29 Importantly, the IRE1α-XBP1s axis not only regulates genes involved in protein folding and ERAD but also directly orchestrates lipid biosynthesis. Under ER stress, XBP1s moves to the nucleus and activates transcriptional programs for fatty acid metabolism, triglyceride synthesis, and cholesterol biogenesis.30,31 Specifically, the metabolic rewiring driven by lipid metabolism is a key driver of HSC activation, a central event in the pathogenesis of liver fibrosis.32 ATF6 ATF6, a transmembrane protein that belongs to the leucine zipper transcription factor family, contains a cytoplasmic bZIP domain essential for transcription factor dimerization. It exists in two isoforms, ATF6α and ATF6β, whose activation is dependent on the dissociation of BiP and the exposure of their Golgi-targeting sequences.33,34 When misfolded or unfolded proteins accumulate, ATF6α translocates to the Golgi apparatus, where it undergoes cleavage by site-1 protease (MBTPS1) and site-2 protease (MBTPS2), releasing a truncated form of ATF6f (ATF6p50) that exhibits activated transcription factor activity.35 Subsequently, ATF6p50 migrates to the nucleus, where it binds to ER stress response elements I or II and induces the transcription and expression of genes such as GRP78, GRP94, C/EBP homologous protein (CHOP), and XBP1.36 PERK PERK is a transmembrane protein with an N-terminal stress-sensing domain and a cytoplasmic kinase domain. During ER stress, PERK dissociates from GRP78 and is activated through dimerization and autophosphorylation.37 To alleviate ER stress, PERK phosphorylates the eukaryotic translation initiation factor 2α (eIF2α) at Ser-51, inhibiting the assembly of the 80S ribosome and preventing mRNA translation initiation, thereby reducing the load of newly synthesized proteins entering the ER lumen.38 Additionally, eIF2α enhances the expression of the transcription factor activating transcription factor 4 (ATF4), which activates CHOP and regulates the expression of growth arrest and DNA damage-inducible protein 34 (GADD34).39 This response promotes the dephosphorylation of eIF2α, restoring protein translation after ER damage. In this process, CHOP can also act as a pro-apoptotic factor by triggering caspase-8 through death receptor 5 (DR5).40 Figure 1. Figure 1The unfolded protein response pathway. (A) IRE1 Pathway: BiP dissociation triggers IRE1 dimerization and RNase activation. IRE1 splices XBP1u mRNA to produce the active transcription factor XBP1s, which drives expression of ER cghaperones, ERAD and lipid metabolism genes. (B) ATF6 Pathway: Released ATF6 translocates to the Golgi for proteolytic cleavage. The cytosolic fragment (ATF6p50) moves to the nucleus to upregulate chaperones like GRP78 and XBP1. (C) PERK Pathway: Active PERK phosphorylates eIF2α, attenuating global protein synthesis while selectively translating ATF4. ATF4 induces genes for stress response and, under prolonged stress, the pro-apoptotic factor CHOP. The unfolded protein response pathway. (A) IRE1 Pathway: BiP dissociation triggers IRE1 dimerization and RNase activation. IRE1 splices XBP1u mRNA to produce the active transcription factor XBP1s, which drives expression of ER cghaperones, ERAD and lipid metabolism genes. (B) ATF6 Pathway: Released ATF6 translocates to the Golgi for proteolytic cleavage. The cytosolic fragment (ATF6p50) moves to the nucleus to upregulate chaperones like GRP78 and XBP1. (C) PERK Pathway: Active PERK phosphorylates eIF2α, attenuating global protein synthesis while selectively translating ATF4. ATF4 induces genes for stress response and, under prolonged stress, the pro-apoptotic factor CHOP. ER Stress and Liver Fibrosis The homeostasis of the liver is maintained through the synergistic action of diverse cell populations, primarily categorized into parenchymal and non-parenchymal cells. Approximately 65% of liver cells are parenchymal cells, primarily hepatocytes with a minor population of cholangiocytes, which are essential for liver regeneration following injury. Non-parenchymal cells, on the other hand, include HSCs, liver sinusoidal endothelial cells, and various immune components such as macrophages, natural killer cells, and dendritic cells, which collectively contribute to immune surveillance, inflammation regulation, and tissue repair.41–43 ER Stress in Parenchymal Cells In parenchymal cells, particularly hepatocytes, ER stress serves as a critical molecular mechanism linking various hepatic injuries to fibrogenesis. Hepatocytes, being the primary metabolic units of the liver, are exceptionally vulnerable to ER stress due to their high protein synthesis burden and involvement in detoxification processes. Multiple pathogenic pathways converge on ER stress in these cells. For instance, QRICH1 enhances HBV-induced hepatic fibrosis by promoting ER stress-mediated high-mobility group box 1 (HMGB1) translocation and secretion, establishing a pro-fibrotic microenvironment.44 Similarly, GP73 upregulation during HBV infection mediates transforming growth factor β 1 (TGF-β1)-induced fibrogenic effects through the Smad2-ER stress axis in hepatocyte models.45 In metabolic contexts, CYP2E1 promotes liver fibrosis by inducing oxidative stress and ER stress in response to high-cholesterol diets, creating a vicious cycle of hepatocyte damage and inflammation.46 The loss of protective mechanisms also contributes significantly; PCSK9 deficiency exacerbates hepatic steatosis and fibrosis through CD36-mediated lipid accumulation, leading to ER stress and inflammatory activation.47 Conversely, several protective factors mitigate these processes. Fibroblast growth factor 21 (FGF21) demonstrates remarkable hepatoprotective effects by attenuating steatosis, lipotoxicity, and ER stress, thereby reducing the activation of downstream fibrogenic pathways.48 GDF15 similarly suppresses fibrosis-related genes and alleviates NASH phenotypes through modulation of ER stress responses.49 The transcription factor CHOP, a key mediator of ER stress-induced apoptosis, is upregulated in various fibrotic models and promotes fibrosis not only through hepatocyte death but also by facilitating alternative activation of pro-fibrotic macrophages in schistosomiasis models.50 Additionally, TRC8 deficiency exacerbates NASH progression by enhancing ER stress and apoptosis, while its overexpression ameliorates these effects, highlighting its crucial role in maintaining ER protein homeostasis in hepatocytes.51 These findings collectively demonstrate that ER stress in parenchymal cells acts as both a sensor of hepatic injury and an active contributor to the fibrotic cascade through multiple interconnected mechanisms. ER Stress in Non-Parenchymal Cells The role of ER stress in non-parenchymal cells, particularly HSCs and immune cells, represents a crucial mechanism in fibrosis progression. In HSCs, ER stress is not merely a consequence of activation but actively drives their transition to pro-fibrotic myofibroblasts. The thiol-disulfide oxidoreductase TXNDC5 is significantly upregulated in activated HSCs, where it promotes cell viability and collagen production through ER stress modulation, making it a promising therapeutic target.52 Similarly, Derlin-1 accelerates NASH progression by enhancing ERAD activity and ER stress, leading to RIPK3-mediated necroptosis in HSCs.53 The collagen secretion machinery in HSCs is intimately connected to ER homeostasis. TANGO1, an ER-resident protein essential for collagen transport, is upregulated during HSC activation in an XBP1-dependent manner. Its depletion causes procollagen I retention, inducing severe UPR activation and ultimately HSC apoptosis.54 Ion channels play a pivotal role in modulating ER stress and its downstream effects in HSCs, thereby influencing liver fibrosis. For instance, the acid-sensing ion channel 1a (ASIC1a) promotes HSC activation primarily by facilitating proton and calcium influx. This disruption of ionic homeostasis, particularly calcium overload within the ER lumen, impairs chaperone function and protein folding, thereby activating the UPR. The ensuing ER stress then drives fibrogenesis through the PI3K/AKT pathway.55,56 The UPR branches play distinct roles, with IRE1α signaling typically promoting fibrogenesis, while AT2R attenuates fibrosis by suppressing the IRE1α-XBP1 pathway in HSCs.57 In immune cells, particularly macrophages, ER stress significantly influences fibrotic progression. IRE1α activation in macrophages promotes pyroptosis and accelerates MASH progression through the IRE1α-GSDMD pathway, with its inhibition showing protective effects.58 CHOP promotes liver fibrosis in schistosomiasis by facilitating alternative macrophage activation and M2 polarization.50 Additionally, adipocyte-derived factors contribute to this network; PCPE1 functions as a BAT-derived profibrotic adipokine that promotes liver fibrosis through ER stress-induced secretion.59 The interplay between different non-parenchymal cells further complicates the ER stress-fibrosis axis. HMGB1 released from injured hepatocytes activates HSCs via toll-like receptor 4(TLR4)/RAGE-mediated ER stress, creating a paracrine loop that sustains fibrogenesis.60 Meanwhile, protective mechanisms also exist; Atp6v0d2 maintains hepatic lipid homeostasis and suppresses MASH progression by inhibiting XBP1-regulated ER stress in macrophages.61 These findings highlight the complex, cell-type-specific roles of ER stress in non-parenchymal cells and emphasize the potential of targeted therapies that modulate specific ER stress pathways in different cell populations to combat liver fibrosis. In summary, ER stress serves as a pivotal pathogenic link that connects diverse hepatic injuries to the progression of liver fibrosis. It orchestrates fibrogenesis through cell-type-specific mechanisms: in parenchymal cells, such as hepatocytes, ER stress promotes apoptosis, inflammatory signaling, and the release of pro-fibrotic factors. Concurrently, in non-parenchymal cells, it directly activates HSCs and modulates immune responses, including macrophage polarization. The intricate cross-talk between these cell populations, particularly between injured hepatocytes and HSCs, as shown in Figure 2. This multifaceted involvement highlights the therapeutic potential of targeting cell-specific ER stress pathways as a promising strategy to mitigate liver fibrosis. Table 1. Table 1Genetic Regulators of Liver Fibrosis via ER Stress PathwaysGeneExperiment ModelER StressConclusionReferenceQRICH1In vivo chronic rcccDNA mouse modelPromoteQRICH1 enhances HBV-induced fibrosis via ER stress-mediated HMGB1 translocation and secretion.[44]HMGB1In vitro hepatocyte/HSC modelsIn vivo fibrosis modelsPromoteHMGB1 from injured hepatocytes activates HSCs via TLR4/RAGE-mediated ER stress, promoting fibrosis.[60]DERLIN1In vivo WD-induced NASH micePromoteDerlin-1 accelerates NASH by enhancing ERAD and ER stress, leading to RIPK3-mediated necroptosis.[53]TANGO1In vivo CCl4/BDL modelsIn vitro HSCsPromoteTANGO1 is essential for collagen I secretion and fibrogenesis via UPR induction.[54]TXNDC5In vivo CCl4 modelIn vitro LX-2 cellsPromoteTXNDC5 knockdown alleviates fibrosis by regulating ER stress in activated HSCs.[52]ASIC1AIn vivo CCl4 modelIn vitro HSC-T6 cellsPromoteASIC1a promotes fibrosis via PI3K/AKT pathway-induced ER stress in HSCs.[55]PCPE1In vivo high-calorie diet MASH modelPromotePCPE1 is a BAT-derived adipokine that promotes liver fibrosis through ER stress.[59]GSDMEIn vivo CDHFD/HFHC MASH modelsPromoteGSDME promotes MASH via pyroptosis, mitochondrial dysfunction, and ER stress.[62]KLF10In vivo high-sucrose diet miceIn vitro hepatocytesPromoteKLF10 deficiency exacerbates fibrosis by promoting ER stress and Smad3 signaling.[63]ASK1In vitro human LX-2 cellsPromoteASK1 mediates Ang II–induced ER stress, exosome release, and HSC activation.[64]CYP2E1In vivo high-cholesterol fast-food diet micePromoteCYP2E1 promotes fibrosis by inducing oxidative stress, ER stress, and inflammation.[46]IRE1AIn vivo and in vitro ER stress and MASH modelsPromoteIRE1α promotes pyroptosis and accelerates MASH via the IRE1α-GSDMD pathway.[58]CHOPIn vivo S. japonicum-infected mouse modelPromoteCHOP promotes liver fibrosis in schistosomiasis by facilitating M2 macrophage polarization.[50]ATF6In vivo TAA-induced acute injury modelPromoteATF6 promotes macrophage-derived cytokine expression and fibrogenesis through ER stress.[65]CIRCADIANIn vivo CCl4 modelIn vitro LX-2 cellsPromoteCirc_0044226 knockdown attenuates fibrosis by sponging miR-4677-3p to suppress SEC61G and ER stress.[66]GP73In vitro HepG2.2.15 cellsPromoteGP73 knockdown impedes fibrosis via mediating ER stress through the Smad2 pathway.[45]TRC8In vivo HFD/MCD diet micePromoteTRC8 deficiency exacerbates NASH by enhancing ER stress and apoptosis.[51]ASAH1In vivo Paigen diet miceIn vitro hepatocytesPromoteAsah1 deletion exacerbates steatosis and fibrosis by increasing ceramide and ER stress.[67]FOXA2In vivo CCl4-treated micePromoteFOXA2 reduction in fibrotic livers contributes to ER stress and hepatocyte apoptosis.[68]PCSK9In vivo HFD modelIn vitro hepatocytesPromotePCSK9 deficiency increases lipid uptake via CD36, leading to steatosis, ER stress, and fibrosis.[47]HRCIn vivo fibrotic liverIn vitro HSCsPromoteHRC knockdown inhibits HSC activation and fibrogenesis through the ER stress pathway.[69]CCN1In vitro primary HSC, LX-2, CFSC-2GPromoteCCN1 induces HSC apoptosis through ER stress and UPR, reducing collagen I and attenuating fibrosis.[70]MIST1In vivo CCl4 modelIn vitro HepG2 cellsPromoteMIST1 regulates apoptosis and TRIB3 expression, indicating liver disease progression.[71]SESTRIN2In vivo BDL modelIn vitro HepG2 cellsInhibitSestrin2 protects against injury and fibrosis by inhibiting mTOR and ER stress.[72]ATP6V0D2In vivo diet-induced obesity modelsInhibitAtp6v0d2 suppresses MASH by inhibiting XBP1-regulated ER stress in macrophages.[61]FGF21In vivo MASLD modelInhibitFGF21 attenuates steatosis, lipotoxicity, ER stress, and inflammation, with anti-fibrotic effects.[48]GCLCIn vitro LX-2 cellsInhibitGCLC reduces oxidative and ER stress, inhibiting pro-inflammatory/fibrogenic pathways in HCV.[73]FAM134BIn vivo ALF mouse modelIn vitro JS-1/RAW264.7 cellsInhibitFAM134B-mediated ER-phagy alleviates ER stress, reducing liver fibrosis and inflammation.[74]AT2RIn vivo fibrotic mouse modelsInhibitAT2R attenuates fibrosis by suppressing the IRE1α-XBP1 pathway and forming a negative feedback loop.[57]CAV1In vivo CAV1 KO MASLD mo In vitro modelInhibitCAV1 alleviates MASLD by maintaining cholesterol homeostasis and suppressing ER stress.[75]MAP4K4In vitro human hepatocytesInhibitMAP4K4 silencing alleviates hepatocyte lipotoxicity by regulating metabolism and ER stress.[76]GDF15In vivo NASH modelsInhibitGDF15 suppresses fibrosis-related genes and osteopontin, alleviating NASH phenotypes.[49]GDF10In vivo diet-induced steatosis modelIn vitro hepatocytesInhibitGDF10 blocks de novo lipogenesis, protecting against ER stress and liver injury.[77]miRNA-29AIn vivo BDL modelIn vitro T6 cellsInhibitmiR-29a overexpression protects against fibrosis by stabilizing ER integrity and reducing ER stress.[78]miRNA-26AIn vitro FFA-loaded HepG2 cellsInhibitmiR-26a regulates lipid metabolism, reduces ER stress and fibrosis markers, enhancing autophagy.[79]CTRP7In vivo HFD-induced obesity modelInhibitCTRP7 deficiency reduces liver fibrosis and ER stress in obese mice.[80]PLIN2In vivo MCD diet NASH modelInhibitPlin2 ablation alleviates steatosis and fibrosis by enhancing PEMT and reducing ER stress.[81]AMPKA2In vivo HFD-induced MAFLD modelInhibitHepatic AMPKα2 knockout alleviates steatosis by inhibiting IRE1α-JNK and reducing autophagy.[82]PLa2BIn vivo MCD diet-induced lean NASH modelInhibitiPla2β deficiency disrupts ER phospholipids, inactivates UPR, and promotes fibrosis.[83]BI1In vivo HFD NAFLD modelInhibitBI-1 deficiency exacerbates IRE1α-dependent NLRP3 activation; IRE1α inhibition rescues NASH.[84] Figure 2Cross-talk between hepatocytes and stellate cells in the formation of fibrosis. Injured hepatocytes release HMGB1, TGF-β1, and ROS, activating HSCs into myofibroblasts. Activated HSCs secrete collagen, cytokines (eg, IL-6, TNF-α), and ROS, exacerbating hepatocyte damage and ER stress. Key pathways include TLR4/RAGE signaling, UPR activation, and oxidative stress. ER stress in hepatocytes promotes apoptosis and inflammatory signaling, while in HSCs, it drives collagen production and myofibroblast transition. The paracrine loop sustains fibrosis through HMGB1, TGF-β1, and ROS. Therapeutic targets include TXNDC5, IRE1α, and ASIC1a to disrupt this pathological interaction, highlighting the complex interplay between hepatocytes and HSCs in liver fibrosis progression. Table 1Genetic Regulators of Liver Fibrosis via ER Stress PathwaysGeneExperiment ModelER StressConclusionReferenceQRICH1In vivo chronic rcccDNA mouse modelPromoteQRICH1 enhances HBV-induced fibrosis via ER stress-mediated HMGB1 translocation and secretion.[44]HMGB1In vitro hepatocyte/HSC modelsIn vivo fibrosis modelsPromoteHMGB1 from injured hepatocytes activates HSCs via TLR4/RAGE-mediated ER stress, promoting fibrosis.[60]DERLIN1In vivo WD-induced NASH micePromoteDerlin-1 accelerates NASH by enhancing ERAD and ER stress, leading to RIPK3-mediated necroptosis.[53]TANGO1In vivo CCl4/BDL modelsIn vitro HSCsPromoteTANGO1 is essential for collagen I secretion and fibrogenesis via UPR induction.[54]TXNDC5In vivo CCl4 modelIn vitro LX-2 cellsPromoteTXNDC5 knockdown alleviates fibrosis by regulating ER stress in activated HSCs.[52]ASIC1AIn vivo CCl4 modelIn vitro HSC-T6 cellsPromoteASIC1a promotes fibrosis via PI3K/AKT pathway-induced ER stress in HSCs.[55]PCPE1In vivo high-calorie diet MASH modelPromotePCPE1 is a BAT-derived adipokine that promotes liver fibrosis through ER stress.[59]GSDMEIn vivo CDHFD/HFHC MASH modelsPromoteGSDME promotes MASH via pyroptosis, mitochondrial dysfunction, and ER stress.[62]KLF10In vivo high-sucrose diet miceIn vitro hepatocytesPromoteKLF10 deficiency exacerbates fibrosis by promoting ER stress and Smad3 signaling.[63]ASK1In vitro human LX-2 cellsPromoteASK1 mediates Ang II–induced ER stress, exosome release, and HSC activation.[64]CYP2E1In vivo high-cholesterol fast-food diet micePromoteCYP2E1 promotes fibrosis by inducing oxidative stress, ER stress, and inflammation.[46]IRE1AIn vivo and in vitro ER stress and MASH modelsPromoteIRE1α promotes pyroptosis and accelerates MASH via the IRE1α-GSDMD pathway.[58]CHOPIn vivo S. japonicum-infected mouse modelPromoteCHOP promotes liver fibrosis in schistosomiasis by facilitating M2 macrophage polarization.[50]ATF6In vivo TAA-induced acute injury modelPromoteATF6 promotes macrophage-derived cytokine expression and fibrogenesis through ER stress.[65]CIRCADIANIn vivo CCl4 modelIn vitro LX-2 cellsPromoteCirc_0044226 knockdown attenuates fibrosis by sponging miR-4677-3p to suppress SEC61G and ER stress.[66]GP73In vitro HepG2.2.15 cellsPromoteGP73 knockdown impedes fibrosis via mediating ER stress through the Smad2 pathway.[45]TRC8In vivo HFD/MCD diet micePromoteTRC8 deficiency exacerbates NASH by enhancing ER stress and apoptosis.[51]ASAH1In vivo Paigen diet miceIn vitro hepatocytesPromoteAsah1 deletion exacerbates steatosis and fibrosis by increasing ceramide and ER stress.[67]FOXA2In vivo CCl4-treated micePromoteFOXA2 reduction in fibrotic livers contributes to ER stress and hepatocyte apoptosis.[68]PCSK9In vivo HFD modelIn vitro hepatocytesPromotePCSK9 deficiency increases lipid uptake via CD36, leading to steatosis, ER stress, and fibrosis.[47]HRCIn vivo fibrotic liverIn vitro HSCsPromoteHRC knockdown inhibits HSC activation and fibrogenesis through the ER stress pathway.[69]CCN1In vitro primary HSC, LX-2, CFSC-2GPromoteCCN1 induces HSC apoptosis through ER stress and UPR, reducing collagen I and attenuating fibrosis.[70]MIST1In vivo CCl4 modelIn vitro HepG2 cellsPromoteMIST1 regulates apoptosis and TRIB3 expression, indicating liver disease progression.[71]SESTRIN2In vivo BDL modelIn vitro HepG2 cellsInhibitSestrin2 protects against injury and fibrosis by inhibiting mTOR and ER stress.[72]ATP6V0D2In vivo diet-induced obesity modelsInhibitAtp6v0d2 suppresses MASH by inhibiting XBP1-regulated ER stress in macrophages.[61]FGF21In vivo MASLD modelInhibitFGF21 attenuates steatosis, lipotoxicity, ER stress, and inflammation, with anti-fibrotic effects.[48]GCLCIn vitro LX-2 cellsInhibitGCLC reduces oxidative and ER stress, inhibiting pro-inflammatory/fibrogenic pathways in HCV.[73]FAM134BIn vivo ALF mouse modelIn vitro JS-1/RAW264.7 cellsInhibitFAM134B-mediated ER-phagy alleviates ER stress, reducing liver fibrosis and inflammation.[74]AT2RIn vivo fibrotic mouse modelsInhibitAT2R attenuates fibrosis by suppressing the IRE1α-XBP1 pathway and forming a negative feedback loop.[57]CAV1In vivo CAV1 KO MASLD mo In vitro modelInhibitCAV1 alleviates MASLD by maintaining cholesterol homeostasis and suppressing ER stress.[75]MAP4K4In vitro human hepatocytesInhibitMAP4K4 silencing alleviates hepatocyte lipotoxicity by regulating metabolism and ER stress.[76]GDF15In vivo NASH modelsInhibitGDF15 suppresses fibrosis-related genes and osteopontin, alleviating NASH phenotypes.[49]GDF10In vivo diet-induced steatosis modelIn vitro hepatocytesInhibitGDF10 blocks de novo lipogenesis, protecting against ER stress and liver injury.[77]miRNA-29AIn vivo BDL modelIn vitro T6 cellsInhibitmiR-29a overexpression protects against fibrosis by stabilizing ER integrity and reducing ER stress.[78]miRNA-26AIn vitro FFA-loaded HepG2 cellsInhibitmiR-26a regulates lipid metabolism, reduces ER stress and fibrosis markers, enhancing autophagy.[79]CTRP7In vivo HFD-induced obesity modelInhibitCTRP7 deficiency reduces liver fibrosis and ER stress in obese mice.[80]PLIN2In vivo MCD diet NASH modelInhibitPlin2 ablation alleviates steatosis and fibrosis by enhancing PEMT and reducing ER stress.[81]AMPKA2In vivo HFD-induced MAFLD modelInhibitHepatic AMPKα2 knockout alleviates steatosis by inhibiting IRE1α-JNK and reducing autophagy.[82]PLa2BIn vivo MCD diet-induced lean NASH modelInhibitiPla2β deficiency disrupts ER phospholipids, inactivates UPR, and promotes fibrosis.[83]BI1In vivo HFD NAFLD modelInhibitBI-1 deficiency exacerbates IRE1α-dependent NLRP3 activation; IRE1α inhibition rescues NASH.[84] Genetic Regulators of Liver Fibrosis via ER Stress Pathways Cross-talk between hepatocytes and stellate cells in the formation of fibrosis. Injured hepatocytes release HMGB1, TGF-β1, and ROS, activating HSCs into myofibroblasts. Activated HSCs secrete collagen, cytokines (eg, IL-6, TNF-α), and ROS, exacerbating hepatocyte damage and ER stress. Key pathways include TLR4/RAGE signaling, UPR activation, and oxidative stress. ER stress in hepatocytes promotes apoptosis and inflammatory signaling, while in HSCs, it drives collagen production and myofibroblast transition. The paracrine loop sustains fibrosis through HMGB1, TGF-β1, and ROS. Therapeutic targets include TXNDC5, IRE1α, and ASIC1a to disrupt this pathological interaction, highlighting the complex interplay between hepatocytes and HSCs in liver fibrosis progression. ER Stress-Targeting Natural Compound ER stress is increasingly recognized as a central mechanism driving hepatic fibrogenesis, drawing significant interest as a therapeutic target. A wide array of natural compounds demonstrates potent anti-fibrotic efficacy by modulating ER stress pathways. These substances can be functionally grouped into two strategic categories: one that suppresses detrimental ER stress to preserve hepatocyte function and inhibit HSCs activation, and another that selectively induces pro-apoptotic ER stress in activated HSCs, promoting their elimination. Compounds That Ameliorate ER Stress Numerous natural compounds alleviate liver fibrosis primarily by inhibiting maladaptive unfolded protein response (UPR) signaling, which in turn reduces hepatocyte apoptosis, inflammation, and HSC activation. Among these, polyphenols and flavonoids constitute a prominently effective class. For example, resveratrol downregulates pivotal ER stress markers such as CHOP, Bip, and caspases-3/7/12, while concurrently inhibiting pro-inflammatory pathways like TGF-β and NF-κB in carbon tetrachloride (CCl4)-induced rodent models and in vitro HSC cultures.85 Similarly, didymin exerts a broad inhibitory effect across all three UPR sensors, such as ATF6, IRE1α, and PERK, thereby mitigating apoptotic signaling and abnormal glycerophospholipid metabolism.86 Additional flavonoids, including naringenin and tetrahydropalmatine, suppress critical UPR axes such as PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1, significantly attenuating fibrotic progression.87,88 Beyond polyphenols, several alkaloids and organic acids also play crucial roles. Berberine specifically targets the ATF6/SREBP-1c pathway, reducing lipid synthesis and ER stress, which leads to improved hepatic steatosis and fibrosis in metabolic models.89 Likewise, p-coumaric acid and oxymatrine alleviate oxidative and ER stress, with oxymatrine notably enhancing calcium homeostasis in HSCs through regulation of Sarco/endoplasmic reticulum Ca2⁺-ATPase 2 (SERCA2).90,91 Among terpenoids and other structurally distinct compounds, additional mechanisms emerge. Irisin modulates PERK phosphorylation to stabilize the RNA-binding protein HNRNPA1, thereby conferring protection against fibrotic signaling.92 Meanwhile, lycopene inhibits the apoptosis signal-regulating kinase 1 (ASK1)-JNK pathway, and tanshinone IIA activates the PPARα/FGF21 axis, both resulting in suppression of ER stress and fibrosis in non-alcoholic steatohepatitis (NASH) models.93,94 Furthermore, salvianolic acid A activates SIRT1, leading to HSF1 deacetylation and subsequent downregulation of the UPR, offering another layer of protection against HSC activation.95 Compounds That Induce Pro-Apoptotic ER Stress in Activated HSCs In contrast, a complementary anti-fibrotic strategy employs natural compounds to selectively induce lethal levels of ER stress in activated HSCs, triggering their apoptosis and facilitating the clearance of these key fibrogenic cells. Quinones and terpenoids are notably effective in this regard. Cryptotanshinone promotes activated HSC apoptosis by upregulating ER stress markers including CHOP and GRP78 and activating UPR-related molecules such as PERK, IRE1α, and ATF4.96 Curcumol, a sesquiterpenoid, uniquely provokes necroptosis in activated HSCs via RIP3, a process modulated through Sirt1/Notch signaling under ER stress conditions.97 Flavonoids also contribute significantly to this targeted approach. Quercetin and oroxylin A effectively initiate ER stress pathway activation, resulting in increased CHOP expression, altered Bcl-2-associated X protein (Bax)/ B-cell lymphoma 2 (Bcl-2) ratios, and caspase activation, collectively driving activated HSC apoptosis.96,98 Similarly, malvidin induces programmed cell death through both ER stress and mitochondrial pathways.99 Even some synthetic agents, such as etoposide, operate through this mechanism, inducing ER stress and JNK-mediated apoptosis in human HSC line LX-2.100 Novel Mechanisms and Emerging Compounds Recent research continues to uncover natural compounds with innovative anti-fibrotic mechanisms centered on ER stress modulation. For instance, 12-deoxyphorbol 13-palmitate represents a novel strategy by specifically targeting the protein Apolipoprotein L2 (APOL2), disrupting its interaction with SERCA2, and thereby inhibiting the pro-fibrotic PERK–HES1 signaling cascade.101 Another compound, senkyunolide A, exhibits specificity for cholestatic fibrosis models. It binds to CLCC1 and promotes its ubiquitination, which inhibits ER calcium release and suppresses ER autophagy, ultimately reducing cholangiocyte proliferation and ductular reaction.102 Additionally, arctigenin mitigates HSC activation through dual mechanisms: not only does it suppress ER stress, but it also restores lipid homeostasis via modulation of the ERAD pathway, underscoring the interplay between proteostasis and metabolic regulation in liver fibrosis.103 Table 2 Table 2Natural Compounds Targeting ER Stress for Liver FibrosisNatural CompoundsMolecular FormulaExperimental ModelER StressMolecular MechanismConclusionsReference12-deoxyphorbol 13-palmitateC36H58O6 In vitro HSCs modelInhibit Binds to APOL2, disrupts APOL2-SERCA2 interactionInhibits PERK-HES1 signalingMitigates ER stress-induced fibrosis2-deoxyphorbol 13-palmitate targets APOL2, impairing APOL2-SERCA2-PERK-HES1 signaling, and represents a promising lead for liver fibrosis treatment[101]CurcumolC15H24O2CCl4-induced mouse modelIn vitro HSCs modelPromoteInduces necroptosis via RIP3ER stress regulates necroptosis through Sirt1/Notch signalingSirt1-mediated NICD deacetylation inhibits Notch signaling.Curcumol clears activated HSCs via necroptosis; alleviates fibrosis through Sirt1/Notch signaling[97]IrisinC24H26O13 CCl4-induced mouse modelIn vitro HSCs modelInhibit Regulates PERK phosphorylation to improve HNRNPA1 stabilityHNRNPA1 knockdown eliminates hepatoprotective effects.Irisin mitigates liver fibrosis by inhibiting PERK-mediated HNRNPA1 destabilization[92]DidyminC28H34O14CCl4-induced mouse modelInhibitInhibits ER stress by regulating ATF6, IRE1α, and PERK pathwaysAlleviates apoptosis via Bcl-2/caspase axisReduces inflammation by decreasing IL-1β/IL-6Inhibits glycerophospholipid metabolism.Didymin ameliorates liver fibrosis by inhibiting ER stress, inflammation and glycerophospholipid metabolism[86]TetrahydropalmatineC21H25NO4 CCl4-induced mouse modelIn vitro HSCs modelInhibit Inhibits ER stress by suppressing PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 pathwaysInhibits HSC activation via ERK1/2 pathway.Tetrahydropalmatine attenuates liver fibrosis by suppressing ER stress pathways in HSCs[87]ResveratrolC14H12O3CCl4-induced rat modelIn vitro HSCs modelInhibitInhibits ER stress by downregulating CHOP, Bip, caspase-3/7/12, Bax, and Bak, and upregulating Bcl-2Reduces inflammation by inhibiting TGF-β, TNF-α, IL-6, and NF-κB pathwaysReverses epithelial-mesenchymal transition by regulating E-cadherin, N-cadherin, vimentin, and α-SMA.Resveratrol ameliorates hepatic fibrosis by reducing ER stress-induced apoptosis and inflammation[85]6-shogaolC17H24O3 MCD diet-induced NASH mouse modelInhibit Inhibits oxidative stress by restoring glutathione levels and regulating pro-oxidant/antioxidant enzymesInhibits apoptosis and necroptosis by downregulating associated proteinsAlleviates ER stress by suppressing UPR pathway molecules.6-shogaol is a potential therapeutic agent for NASH by targeting oxidative stress, cell death and ER stress[104]Senkyunolide AC12H16O2BDL mouse modelPrimary and human cholangiocytesInhibitInhibits ER Ca2+ release by binding to and promoting ubiquitination of CLCC1Suppresses RYR channel activity to prevent Ca2+ transients and ER autophagy.Senkyunolide A inhibits cholangiocyte proliferation and alleviates cholestatic fibrosis by controlling ER Ca2+ release, suppressing ER autophagy, and reversing ductular reaction.[102]LycopeneC40H56 HFHC diet or MCD diet mouse modelIn vitro HepG2 cellsInhibit Inhibits ASK1-JNK pathway and IRE1α activity to reduce ER stress markers (BiP, CHOP, XBP1s) and inflammation.Attenuates lipid accumulation and fibrosisLycopene alleviates NASH by inhibiting ASK1-JNK pathway, reducing ER stress and inflammation[93]Tanshinone IIAC19H18O3MCD diet-induced NASH mouse modelInhibitActivates PPARα/FGF21 axis to negatively regulate ER stress-induced UPRModulates NOD-like receptor signaling and phospholipid metabolism to reduce inflammation and fibrosis.Tanshinone IIA alleviates NASH by activating PPARα/FGF21 to inhibit ER stress and UPR, reduce lipid accumulation, inflammation, and fibrosis.[94]DiacereinC19H12O8 BDL-induced rat modelInhibit Inhibits HMGB1/RAGE/NF-κB/JNK pathway to reduce inflammationDownregulates ER stress markers (GRP78, IRE1α, PERK, CHOP, p-JNK) and fibrogenic mediators (TGF-β1, α-SMA, collagen 1, hydroxyproline).Diacerein exhibits dose-dependent antifibrotic effects by inhibiting HMGB1/RAGE/NF-κB/JNK pathway and ER stress.[105]Salvianolic acid AC26H22O10BDL-induced rat modelIn vitro LX2 cellsInhibitActivates SIRT1 to promote HSF1 deacetylation, thereby reducing ER stressInhibits PDGF-BB-induced fibrosis in LX2 cells.Confers protection against liver fibrosis through SIRT1-mediated HSF1 deacetylation.[95]HydronidoneC12H11NO2 CCl4- and DDC-induced mouse modelsIn vitro LX2 cellsPromote Triggers ER stress to activate IRE1α-ASK1-JNK pathwayInduces mitochondrial dysfunction and cytochrome c release, leading to apoptosis in activated HSCs.Hydronidone induces apoptosis in activated HSCs via ER stress-associated mitochondrial pathway to ameliorate liver fibrosis[106]QuercetinC15H10O7In vitro HSCs and hepatocytesPromoteActivates ER stress pathway (PERK, IRE1, ATF6, calnexin, CHOP) to induce HSC apoptosisDownregulates Bcl-2, upregulates Bax, and increases caspase-9, caspase-3, and PARP-1 cleavage.Quercetin activates ER stress pathway leading to HSC apoptosis, a promising antifibrotic agent[98]ArctigeninC21H24O6 Primary rat HSCsInhibit Suppresses ER stress markers (GRP78) and fibrotic marker α-SMA; restores lipid homeostasis via modulation of DGAT2, PPAR-γ, ATGL, and ERAD pathwayNormalizes ERAD-mediated lipid dysregulation.Arctigenin mitigates HSC activation by suppressing ER stress and restoring lipid homeostasis via modulation of ERAD-mediated lipid dysregulation; emerges as a promising therapeutic candidate for liver fibrosis.[103]MalvidinC17H15O7In vitro HSC-T6 cellsPromoteInduces HSC apoptosis via ER stress (Caspase-12, GRP78, CHOP) and mitochondrial pathways (Caspase-3, Bax, Bcl-2)Increases malondialdehyde levels.Malvidin induces HSC apoptosis via ER stress and mitochondrial pathways, potential functional food ingredient for liver health[99]NaringeninC15H12O5 CCl4-induced rat modelInhibit Reduces ER stress markers and inhibits autophagy markersAmeliorates liver damage by modulating unfolded protein response and autophagy pathways.Naringenin ameliorates liver damage by reducing ER stress and inhibiting autophagy[88]OxymatrineC15H24N2O2NaAsO2-induced LX2 cellsInhibitAttenuates ER stress by regulating GRP78 and SERCA2Improves calcium homeostasis to inhibit HSC activation and ECM secretion.Oxymatrine improves calcium homeostasis and attenuates ER stress to inhibit HSC activation and ECM secretion[90]Oroxylin AC16H12O5 CCl4-induced mouse modelIn vitro HSCs modelPromote Promotes ER stress-induced apoptosis by upregulating eIF2α and ER stress -related proteinsInhibits HSC activation and hepatic fibrosis.Oroxylin A attenuates HSC activation and hepatic fibrosis by promoting ER stress -induced apoptosis; upregulates eIF2α and ER stress -related proteins to inhibit fibrogenesis.[107]CryptotanshinoneC19H20O3CCl4-induced mouse modelIn vitro HSCs modelPromotePromotes HSC apoptosis by upregulating ER stress markers (CHOP and GRP78) and activating ER stress pathway molecules (PERK, IRE1α, and ATF4)Alleviates hepatic fibrosis by modulating the ER stress pathway.Cryptotanshinone promotes HSC apoptosis and alleviates hepatic fibrosis by activating the ER stress.[96]Ginsenoside Rh2C36H62O8 In vitro HepG2 cells and THP-1 cellsInhibit Inhibits ER stress, lipid synthesis (SREBF1, FAS), and inflammation (IL-6, IL-1β, TNF-α, MCP-1)Modulates macrophage polarization by decreasing M1 markers (CD80, CD86) and increasing M2 markers (CD163, Arg1, MRC-1).Ginsenoside Rh2 suppresses inflammation and lipid storage in ER stress -induced hepatocytes and modulates hepatocyte-macrophage crosstalk.[108]ChrysophanolC15H10O4In vitro HSC-T6 cellsInhibitInhibits HBx-induced HSC activation by downregulating ER stress markers (Bip, CHOP, p-IRE1α) and ferroptosis-related proteins (GPX4, SLC7A11)Attenuates fibrosis markers (α-SMA, CTGF).Chrysophanol impairs HBx-induced HSC activation via ER stress and ferroptosis pathways[17]BerberineC20H18NO4+ Db/db and MCD diet-fed miceIn vitro hepatocytesInhibit Suppresses ER stress and lipogenesis by inhibiting the ATF6/SREBP-1c pathwayReduces lipid accumulation and collagen deposition.Berberine reduces hepatic steatosis and fibrosis by suppressing ER stress through ATF6/SREBP-1c pathway[89]Schisandrin BC23H28O6CCl4-induced rat modelInhibitUpregulation of cytochrome P450 drug metabolism and PPAR signaling, and downregulation of glutathione metabolismAlleviates ER stress and apoptosis.Schisandrin B alleviates liver fibrosis by modulating multiple pathways including ER stress and apoptosis[109]p-Coumaric acidC9H8O3 HFHS diet mouse model.In vitro HSCs modelInhibit Attenuates hepatic fibrosis by inhibiting TLR4/NFκB signaling, NLRP3 inflammasome activationAlleviates ER and oxidative stress.p-Coumaric acid ameliorates hepatic fibrosis by attenuating NLRP3 inflammasome activation and ER stress[91]AllantoinC4H6N4O3MCD diet-induced mouse modelInhibitDownregulating ER stress-related genes (GRP78, ATF6), inflammatory markers (TNFα), lipogenic genes (SREBP1c, FAS), and apoptotic pathways (Bax/Bcl2 ratio, caspase3, P53)Upregulating PPARα, Apo B, and ACAT1 expression.Allantoin improves NASH by modulating ER stress-related genes and apoptotic pathways[110]Total saponins of Panax japonicus (SPJ)Not specified HF diet + porcine serum mouse modelInhibit Inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammationDownregulates Coll, α-SMA, TIMP, CHOP, GRP78, and p-JNK expression.SPJ prevents liver fibrosis by inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammation[111]α-TocopherolC29H50O2CCl4 and BDL mouse modelsInhibitPromoting Nrf2 nuclear translocation, reducing Nrf2 degradationInhibiting autophagy and ER stressIncreasing SQSTM1 competition to bind KEAP1.α-Tocopherol alleviates liver fibrosis by promoting Nrf2 nuclear translocation and inhibiting ER stress[112]Ganoderic acid AC30H44O7 HFHC diet-induced mouse modelInhibit Inhibiting hepatic oxidative stress and ER stress response;Downregulates GRP78, p-eIF2α, and p-JNKUpregulating ERp57, p-MAPK, and p-AKT.Ganoderic acid A resists NASH by inhibiting hepatic oxidative stress and ER stress response[113]KaempferolC15H10O6CCl4-induced rat modelIn vitro HSC-T6 cellsInhibitInteracting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathwayDownregulates ASIC1a, p-eIF2α, ATF-4, VEGF, α-SMA, and Collagen-I.Kaempferol attenuates hepatic fibrosis by interacting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathway[114]18β-Glycyrrhetinic acidC30H46O4 BDL-induced rat modelInhibit Co-activation of Sirt1/FXR/Nrf2 pathways; upregulates Sirt1, FXR, and Nrf2Downregulates TGF-β1/Smad, HMGB1/TLR4, NF-κB, and STAT1.18β-Glycyrrhetinic acid protects against cholestatic liver injury through co-activation of Sirt1/FXR/Nrf2 pathways[115]EtoposideC29H32O13In vitro LX-2 cellsPromoteInduces ER stress and JNK pathwayUpregulates CHOP, BIP, caspase-12, p-eIF2α, IRE1α, and JNKDownregulates α-SMA and Collagen I, and increases MMPs/TIMPs ratio.Etoposide induces HSC apoptosis via ER stress and JNK pathway, exhibits antifibrotic effects[100]Schisandra chinensis derived LignansNot specified EtOH- and CCl4-induced mouse modelIn vitro HL-7702 and LX-2 cellsInhibit Downregulates ETBR, PLCβ, CHOP, Bax, cleaved-caspase 12/9/3, α-SMA, and TGF-β1,Upregulates GSHPrimarily targets ETBR.Schisandra chinensis derived Lignans prevents hepatotoxicity via anti-fibrotic, anti-oxidant, and anti-apoptosis properties, primarily targeting ETBR[116]GeranylgeranylacetoneC23H38OIn vitro LX2 cellsCCl4-induced mouse modelPromoteInduces ER stress and apoptosis in HSCs via upregulation of CHOPGeranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in HSCs, suppresses liver fibrosis in mice[117] Table 2Natural Compounds Targeting ER Stress for Liver FibrosisNatural CompoundsMolecular FormulaExperimental ModelER StressMolecular MechanismConclusionsReference12-deoxyphorbol 13-palmitateC36H58O6 In vitro HSCs modelInhibit Binds to APOL2, disrupts APOL2-SERCA2 interactionInhibits PERK-HES1 signalingMitigates ER stress-induced fibrosis2-deoxyphorbol 13-palmitate targets APOL2, impairing APOL2-SERCA2-PERK-HES1 signaling, and represents a promising lead for liver fibrosis treatment[101]CurcumolC15H24O2CCl4-induced mouse modelIn vitro HSCs modelPromoteInduces necroptosis via RIP3ER stress regulates necroptosis through Sirt1/Notch signalingSirt1-mediated NICD deacetylation inhibits Notch signaling.Curcumol clears activated HSCs via necroptosis; alleviates fibrosis through Sirt1/Notch signaling[97]IrisinC24H26O13 CCl4-induced mouse modelIn vitro HSCs modelInhibit Regulates PERK phosphorylation to improve HNRNPA1 stabilityHNRNPA1 knockdown eliminates hepatoprotective effects.Irisin mitigates liver fibrosis by inhibiting PERK-mediated HNRNPA1 destabilization[92]DidyminC28H34O14CCl4-induced mouse modelInhibitInhibits ER stress by regulating ATF6, IRE1α, and PERK pathwaysAlleviates apoptosis via Bcl-2/caspase axisReduces inflammation by decreasing IL-1β/IL-6Inhibits glycerophospholipid metabolism.Didymin ameliorates liver fibrosis by inhibiting ER stress, inflammation and glycerophospholipid metabolism[86]TetrahydropalmatineC21H25NO4 CCl4-induced mouse modelIn vitro HSCs modelInhibit Inhibits ER stress by suppressing PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 pathwaysInhibits HSC activation via ERK1/2 pathway.Tetrahydropalmatine attenuates liver fibrosis by suppressing ER stress pathways in HSCs[87]ResveratrolC14H12O3CCl4-induced rat modelIn vitro HSCs modelInhibitInhibits ER stress by downregulating CHOP, Bip, caspase-3/7/12, Bax, and Bak, and upregulating Bcl-2Reduces inflammation by inhibiting TGF-β, TNF-α, IL-6, and NF-κB pathwaysReverses epithelial-mesenchymal transition by regulating E-cadherin, N-cadherin, vimentin, and α-SMA.Resveratrol ameliorates hepatic fibrosis by reducing ER stress-induced apoptosis and inflammation[85]6-shogaolC17H24O3 MCD diet-induced NASH mouse modelInhibit Inhibits oxidative stress by restoring glutathione levels and regulating pro-oxidant/antioxidant enzymesInhibits apoptosis and necroptosis by downregulating associated proteinsAlleviates ER stress by suppressing UPR pathway molecules.6-shogaol is a potential therapeutic agent for NASH by targeting oxidative stress, cell death and ER stress[104]Senkyunolide AC12H16O2BDL mouse modelPrimary and human cholangiocytesInhibitInhibits ER Ca2+ release by binding to and promoting ubiquitination of CLCC1Suppresses RYR channel activity to prevent Ca2+ transients and ER autophagy.Senkyunolide A inhibits cholangiocyte proliferation and alleviates cholestatic fibrosis by controlling ER Ca2+ release, suppressing ER autophagy, and reversing ductular reaction.[102]LycopeneC40H56 HFHC diet or MCD diet mouse modelIn vitro HepG2 cellsInhibit Inhibits ASK1-JNK pathway and IRE1α activity to reduce ER stress markers (BiP, CHOP, XBP1s) and inflammation.Attenuates lipid accumulation and fibrosisLycopene alleviates NASH by inhibiting ASK1-JNK pathway, reducing ER stress and inflammation[93]Tanshinone IIAC19H18O3MCD diet-induced NASH mouse modelInhibitActivates PPARα/FGF21 axis to negatively regulate ER stress-induced UPRModulates NOD-like receptor signaling and phospholipid metabolism to reduce inflammation and fibrosis.Tanshinone IIA alleviates NASH by activating PPARα/FGF21 to inhibit ER stress and UPR, reduce lipid accumulation, inflammation, and fibrosis.[94]DiacereinC19H12O8 BDL-induced rat modelInhibit Inhibits HMGB1/RAGE/NF-κB/JNK pathway to reduce inflammationDownregulates ER stress markers (GRP78, IRE1α, PERK, CHOP, p-JNK) and fibrogenic mediators (TGF-β1, α-SMA, collagen 1, hydroxyproline).Diacerein exhibits dose-dependent antifibrotic effects by inhibiting HMGB1/RAGE/NF-κB/JNK pathway and ER stress.[105]Salvianolic acid AC26H22O10BDL-induced rat modelIn vitro LX2 cellsInhibitActivates SIRT1 to promote HSF1 deacetylation, thereby reducing ER stressInhibits PDGF-BB-induced fibrosis in LX2 cells.Confers protection against liver fibrosis through SIRT1-mediated HSF1 deacetylation.[95]HydronidoneC12H11NO2 CCl4- and DDC-induced mouse modelsIn vitro LX2 cellsPromote Triggers ER stress to activate IRE1α-ASK1-JNK pathwayInduces mitochondrial dysfunction and cytochrome c release, leading to apoptosis in activated HSCs.Hydronidone induces apoptosis in activated HSCs via ER stress-associated mitochondrial pathway to ameliorate liver fibrosis[106]QuercetinC15H10O7In vitro HSCs and hepatocytesPromoteActivates ER stress pathway (PERK, IRE1, ATF6, calnexin, CHOP) to induce HSC apoptosisDownregulates Bcl-2, upregulates Bax, and increases caspase-9, caspase-3, and PARP-1 cleavage.Quercetin activates ER stress pathway leading to HSC apoptosis, a promising antifibrotic agent[98]ArctigeninC21H24O6 Primary rat HSCsInhibit Suppresses ER stress markers (GRP78) and fibrotic marker α-SMA; restores lipid homeostasis via modulation of DGAT2, PPAR-γ, ATGL, and ERAD pathwayNormalizes ERAD-mediated lipid dysregulation.Arctigenin mitigates HSC activation by suppressing ER stress and restoring lipid homeostasis via modulation of ERAD-mediated lipid dysregulation; emerges as a promising therapeutic candidate for liver fibrosis.[103]MalvidinC17H15O7In vitro HSC-T6 cellsPromoteInduces HSC apoptosis via ER stress (Caspase-12, GRP78, CHOP) and mitochondrial pathways (Caspase-3, Bax, Bcl-2)Increases malondialdehyde levels.Malvidin induces HSC apoptosis via ER stress and mitochondrial pathways, potential functional food ingredient for liver health[99]NaringeninC15H12O5 CCl4-induced rat modelInhibit Reduces ER stress markers and inhibits autophagy markersAmeliorates liver damage by modulating unfolded protein response and autophagy pathways.Naringenin ameliorates liver damage by reducing ER stress and inhibiting autophagy[88]OxymatrineC15H24N2O2NaAsO2-induced LX2 cellsInhibitAttenuates ER stress by regulating GRP78 and SERCA2Improves calcium homeostasis to inhibit HSC activation and ECM secretion.Oxymatrine improves calcium homeostasis and attenuates ER stress to inhibit HSC activation and ECM secretion[90]Oroxylin AC16H12O5 CCl4-induced mouse modelIn vitro HSCs modelPromote Promotes ER stress-induced apoptosis by upregulating eIF2α and ER stress -related proteinsInhibits HSC activation and hepatic fibrosis.Oroxylin A attenuates HSC activation and hepatic fibrosis by promoting ER stress -induced apoptosis; upregulates eIF2α and ER stress -related proteins to inhibit fibrogenesis.[107]CryptotanshinoneC19H20O3CCl4-induced mouse modelIn vitro HSCs modelPromotePromotes HSC apoptosis by upregulating ER stress markers (CHOP and GRP78) and activating ER stress pathway molecules (PERK, IRE1α, and ATF4)Alleviates hepatic fibrosis by modulating the ER stress pathway.Cryptotanshinone promotes HSC apoptosis and alleviates hepatic fibrosis by activating the ER stress.[96]Ginsenoside Rh2C36H62O8 In vitro HepG2 cells and THP-1 cellsInhibit Inhibits ER stress, lipid synthesis (SREBF1, FAS), and inflammation (IL-6, IL-1β, TNF-α, MCP-1)Modulates macrophage polarization by decreasing M1 markers (CD80, CD86) and increasing M2 markers (CD163, Arg1, MRC-1).Ginsenoside Rh2 suppresses inflammation and lipid storage in ER stress -induced hepatocytes and modulates hepatocyte-macrophage crosstalk.[108]ChrysophanolC15H10O4In vitro HSC-T6 cellsInhibitInhibits HBx-induced HSC activation by downregulating ER stress markers (Bip, CHOP, p-IRE1α) and ferroptosis-related proteins (GPX4, SLC7A11)Attenuates fibrosis markers (α-SMA, CTGF).Chrysophanol impairs HBx-induced HSC activation via ER stress and ferroptosis pathways[17]BerberineC20H18NO4+ Db/db and MCD diet-fed miceIn vitro hepatocytesInhibit Suppresses ER stress and lipogenesis by inhibiting the ATF6/SREBP-1c pathwayReduces lipid accumulation and collagen deposition.Berberine reduces hepatic steatosis and fibrosis by suppressing ER stress through ATF6/SREBP-1c pathway[89]Schisandrin BC23H28O6CCl4-induced rat modelInhibitUpregulation of cytochrome P450 drug metabolism and PPAR signaling, and downregulation of glutathione metabolismAlleviates ER stress and apoptosis.Schisandrin B alleviates liver fibrosis by modulating multiple pathways including ER stress and apoptosis[109]p-Coumaric acidC9H8O3 HFHS diet mouse model.In vitro HSCs modelInhibit Attenuates hepatic fibrosis by inhibiting TLR4/NFκB signaling, NLRP3 inflammasome activationAlleviates ER and oxidative stress.p-Coumaric acid ameliorates hepatic fibrosis by attenuating NLRP3 inflammasome activation and ER stress[91]AllantoinC4H6N4O3MCD diet-induced mouse modelInhibitDownregulating ER stress-related genes (GRP78, ATF6), inflammatory markers (TNFα), lipogenic genes (SREBP1c, FAS), and apoptotic pathways (Bax/Bcl2 ratio, caspase3, P53)Upregulating PPARα, Apo B, and ACAT1 expression.Allantoin improves NASH by modulating ER stress-related genes and apoptotic pathways[110]Total saponins of Panax japonicus (SPJ)Not specified HF diet + porcine serum mouse modelInhibit Inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammationDownregulates Coll, α-SMA, TIMP, CHOP, GRP78, and p-JNK expression.SPJ prevents liver fibrosis by inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammation[111]α-TocopherolC29H50O2CCl4 and BDL mouse modelsInhibitPromoting Nrf2 nuclear translocation, reducing Nrf2 degradationInhibiting autophagy and ER stressIncreasing SQSTM1 competition to bind KEAP1.α-Tocopherol alleviates liver fibrosis by promoting Nrf2 nuclear translocation and inhibiting ER stress[112]Ganoderic acid AC30H44O7 HFHC diet-induced mouse modelInhibit Inhibiting hepatic oxidative stress and ER stress response;Downregulates GRP78, p-eIF2α, and p-JNKUpregulating ERp57, p-MAPK, and p-AKT.Ganoderic acid A resists NASH by inhibiting hepatic oxidative stress and ER stress response[113]KaempferolC15H10O6CCl4-induced rat modelIn vitro HSC-T6 cellsInhibitInteracting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathwayDownregulates ASIC1a, p-eIF2α, ATF-4, VEGF, α-SMA, and Collagen-I.Kaempferol attenuates hepatic fibrosis by interacting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathway[114]18β-Glycyrrhetinic acidC30H46O4 BDL-induced rat modelInhibit Co-activation of Sirt1/FXR/Nrf2 pathways; upregulates Sirt1, FXR, and Nrf2Downregulates TGF-β1/Smad, HMGB1/TLR4, NF-κB, and STAT1.18β-Glycyrrhetinic acid protects against cholestatic liver injury through co-activation of Sirt1/FXR/Nrf2 pathways[115]EtoposideC29H32O13In vitro LX-2 cellsPromoteInduces ER stress and JNK pathwayUpregulates CHOP, BIP, caspase-12, p-eIF2α, IRE1α, and JNKDownregulates α-SMA and Collagen I, and increases MMPs/TIMPs ratio.Etoposide induces HSC apoptosis via ER stress and JNK pathway, exhibits antifibrotic effects[100]Schisandra chinensis derived LignansNot specified EtOH- and CCl4-induced mouse modelIn vitro HL-7702 and LX-2 cellsInhibit Downregulates ETBR, PLCβ, CHOP, Bax, cleaved-caspase 12/9/3, α-SMA, and TGF-β1,Upregulates GSHPrimarily targets ETBR.Schisandra chinensis derived Lignans prevents hepatotoxicity via anti-fibrotic, anti-oxidant, and anti-apoptosis properties, primarily targeting ETBR[116]GeranylgeranylacetoneC23H38OIn vitro LX2 cellsCCl4-induced mouse modelPromoteInduces ER stress and apoptosis in HSCs via upregulation of CHOPGeranylgeranylacetone attenuates fibrogenic activity and induces apoptosis in HSCs, suppresses liver fibrosis in mice[117] Natural Compounds Targeting ER Stress for Liver Fibrosis In vitro HSCs model In vitro HSCs model Binds to APOL2, disrupts APOL2-SERCA2 interaction Binds to APOL2, disrupts APOL2-SERCA2 interaction Inhibits PERK-HES1 signaling Inhibits PERK-HES1 signaling Mitigates ER stress-induced fibrosis Mitigates ER stress-induced fibrosis CCl4-induced mouse model CCl4-induced mouse model In vitro HSCs model In vitro HSCs model Induces necroptosis via RIP3 Induces necroptosis via RIP3 ER stress regulates necroptosis through Sirt1/Notch signaling ER stress regulates necroptosis through Sirt1/Notch signaling Sirt1-mediated NICD deacetylation inhibits Notch signaling. Sirt1-mediated NICD deacetylation inhibits Notch signaling. CCl4-induced mouse model CCl4-induced mouse model In vitro HSCs model In vitro HSCs model Regulates PERK phosphorylation to improve HNRNPA1 stability Regulates PERK phosphorylation to improve HNRNPA1 stability HNRNPA1 knockdown eliminates hepatoprotective effects. HNRNPA1 knockdown eliminates hepatoprotective effects. CCl4-induced mouse model CCl4-induced mouse model Inhibits ER stress by regulating ATF6, IRE1α, and PERK pathways Inhibits ER stress by regulating ATF6, IRE1α, and PERK pathways Alleviates apoptosis via Bcl-2/caspase axis Alleviates apoptosis via Bcl-2/caspase axis Reduces inflammation by decreasing IL-1β/IL-6 Reduces inflammation by decreasing IL-1β/IL-6 Inhibits glycerophospholipid metabolism. Inhibits glycerophospholipid metabolism. CCl4-induced mouse model CCl4-induced mouse model In vitro HSCs model In vitro HSCs model Inhibits ER stress by suppressing PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 pathways Inhibits ER stress by suppressing PERK-eIF2α-ATF4-CHOP and IRE1α-XBP1 pathways Inhibits HSC activation via ERK1/2 pathway. Inhibits HSC activation via ERK1/2 pathway. CCl4-induced rat model CCl4-induced rat model In vitro HSCs model In vitro HSCs model Inhibits ER stress by downregulating CHOP, Bip, caspase-3/7/12, Bax, and Bak, and upregulating Bcl-2 Inhibits ER stress by downregulating CHOP, Bip, caspase-3/7/12, Bax, and Bak, and upregulating Bcl-2 Reduces inflammation by inhibiting TGF-β, TNF-α, IL-6, and NF-κB pathways Reduces inflammation by inhibiting TGF-β, TNF-α, IL-6, and NF-κB pathways Reverses epithelial-mesenchymal transition by regulating E-cadherin, N-cadherin, vimentin, and α-SMA. Reverses epithelial-mesenchymal transition by regulating E-cadherin, N-cadherin, vimentin, and α-SMA. MCD diet-induced NASH mouse model MCD diet-induced NASH mouse model Inhibits oxidative stress by restoring glutathione levels and regulating pro-oxidant/antioxidant enzymes Inhibits oxidative stress by restoring glutathione levels and regulating pro-oxidant/antioxidant enzymes Inhibits apoptosis and necroptosis by downregulating associated proteins Inhibits apoptosis and necroptosis by downregulating associated proteins Alleviates ER stress by suppressing UPR pathway molecules. Alleviates ER stress by suppressing UPR pathway molecules. BDL mouse model BDL mouse model Primary and human cholangiocytes Primary and human cholangiocytes Inhibits ER Ca2+ release by binding to and promoting ubiquitination of CLCC1 Inhibits ER Ca2+ release by binding to and promoting ubiquitination of CLCC1 Suppresses RYR channel activity to prevent Ca2+ transients and ER autophagy. Suppresses RYR channel activity to prevent Ca2+ transients and ER autophagy. HFHC diet or MCD diet mouse model HFHC diet or MCD diet mouse model In vitro HepG2 cells In vitro HepG2 cells Inhibits ASK1-JNK pathway and IRE1α activity to reduce ER stress markers (BiP, CHOP, XBP1s) and inflammation. Inhibits ASK1-JNK pathway and IRE1α activity to reduce ER stress markers (BiP, CHOP, XBP1s) and inflammation. Attenuates lipid accumulation and fibrosis Attenuates lipid accumulation and fibrosis MCD diet-induced NASH mouse model MCD diet-induced NASH mouse model Activates PPARα/FGF21 axis to negatively regulate ER stress-induced UPR Activates PPARα/FGF21 axis to negatively regulate ER stress-induced UPR Modulates NOD-like receptor signaling and phospholipid metabolism to reduce inflammation and fibrosis. Modulates NOD-like receptor signaling and phospholipid metabolism to reduce inflammation and fibrosis. BDL-induced rat model BDL-induced rat model Inhibits HMGB1/RAGE/NF-κB/JNK pathway to reduce inflammation Inhibits HMGB1/RAGE/NF-κB/JNK pathway to reduce inflammation Downregulates ER stress markers (GRP78, IRE1α, PERK, CHOP, p-JNK) and fibrogenic mediators (TGF-β1, α-SMA, collagen 1, hydroxyproline). Downregulates ER stress markers (GRP78, IRE1α, PERK, CHOP, p-JNK) and fibrogenic mediators (TGF-β1, α-SMA, collagen 1, hydroxyproline). BDL-induced rat model BDL-induced rat model In vitro LX2 cells In vitro LX2 cells Activates SIRT1 to promote HSF1 deacetylation, thereby reducing ER stress Activates SIRT1 to promote HSF1 deacetylation, thereby reducing ER stress Inhibits PDGF-BB-induced fibrosis in LX2 cells. Inhibits PDGF-BB-induced fibrosis in LX2 cells. CCl4- and DDC-induced mouse models CCl4- and DDC-induced mouse models In vitro LX2 cells In vitro LX2 cells Triggers ER stress to activate IRE1α-ASK1-JNK pathway Triggers ER stress to activate IRE1α-ASK1-JNK pathway Induces mitochondrial dysfunction and cytochrome c release, leading to apoptosis in activated HSCs. Induces mitochondrial dysfunction and cytochrome c release, leading to apoptosis in activated HSCs. In vitro HSCs and hepatocytes In vitro HSCs and hepatocytes Activates ER stress pathway (PERK, IRE1, ATF6, calnexin, CHOP) to induce HSC apoptosis Activates ER stress pathway (PERK, IRE1, ATF6, calnexin, CHOP) to induce HSC apoptosis Downregulates Bcl-2, upregulates Bax, and increases caspase-9, caspase-3, and PARP-1 cleavage. Downregulates Bcl-2, upregulates Bax, and increases caspase-9, caspase-3, and PARP-1 cleavage. Primary rat HSCs Primary rat HSCs Suppresses ER stress markers (GRP78) and fibrotic marker α-SMA; restores lipid homeostasis via modulation of DGAT2, PPAR-γ, ATGL, and ERAD pathway Suppresses ER stress markers (GRP78) and fibrotic marker α-SMA; restores lipid homeostasis via modulation of DGAT2, PPAR-γ, ATGL, and ERAD pathway Normalizes ERAD-mediated lipid dysregulation. Normalizes ERAD-mediated lipid dysregulation. In vitro HSC-T6 cells In vitro HSC-T6 cells Induces HSC apoptosis via ER stress (Caspase-12, GRP78, CHOP) and mitochondrial pathways (Caspase-3, Bax, Bcl-2) Induces HSC apoptosis via ER stress (Caspase-12, GRP78, CHOP) and mitochondrial pathways (Caspase-3, Bax, Bcl-2) Increases malondialdehyde levels. Increases malondialdehyde levels. CCl4-induced rat model CCl4-induced rat model Reduces ER stress markers and inhibits autophagy markers Reduces ER stress markers and inhibits autophagy markers Ameliorates liver damage by modulating unfolded protein response and autophagy pathways. Ameliorates liver damage by modulating unfolded protein response and autophagy pathways. NaAsO2-induced LX2 cells NaAsO2-induced LX2 cells Attenuates ER stress by regulating GRP78 and SERCA2 Attenuates ER stress by regulating GRP78 and SERCA2 Improves calcium homeostasis to inhibit HSC activation and ECM secretion. Improves calcium homeostasis to inhibit HSC activation and ECM secretion. CCl4-induced mouse model CCl4-induced mouse model In vitro HSCs model In vitro HSCs model Promotes ER stress-induced apoptosis by upregulating eIF2α and ER stress -related proteins Promotes ER stress-induced apoptosis by upregulating eIF2α and ER stress -related proteins Inhibits HSC activation and hepatic fibrosis. Inhibits HSC activation and hepatic fibrosis. CCl4-induced mouse model CCl4-induced mouse model In vitro HSCs model In vitro HSCs model Promotes HSC apoptosis by upregulating ER stress markers (CHOP and GRP78) and activating ER stress pathway molecules (PERK, IRE1α, and ATF4) Promotes HSC apoptosis by upregulating ER stress markers (CHOP and GRP78) and activating ER stress pathway molecules (PERK, IRE1α, and ATF4) Alleviates hepatic fibrosis by modulating the ER stress pathway. Alleviates hepatic fibrosis by modulating the ER stress pathway. In vitro HepG2 cells and THP-1 cells In vitro HepG2 cells and THP-1 cells Inhibits ER stress, lipid synthesis (SREBF1, FAS), and inflammation (IL-6, IL-1β, TNF-α, MCP-1) Inhibits ER stress, lipid synthesis (SREBF1, FAS), and inflammation (IL-6, IL-1β, TNF-α, MCP-1) Modulates macrophage polarization by decreasing M1 markers (CD80, CD86) and increasing M2 markers (CD163, Arg1, MRC-1). Modulates macrophage polarization by decreasing M1 markers (CD80, CD86) and increasing M2 markers (CD163, Arg1, MRC-1). In vitro HSC-T6 cells In vitro HSC-T6 cells Inhibits HBx-induced HSC activation by downregulating ER stress markers (Bip, CHOP, p-IRE1α) and ferroptosis-related proteins (GPX4, SLC7A11) Inhibits HBx-induced HSC activation by downregulating ER stress markers (Bip, CHOP, p-IRE1α) and ferroptosis-related proteins (GPX4, SLC7A11) Attenuates fibrosis markers (α-SMA, CTGF). Attenuates fibrosis markers (α-SMA, CTGF). Db/db and MCD diet-fed mice Db/db and MCD diet-fed mice In vitro hepatocytes In vitro hepatocytes Suppresses ER stress and lipogenesis by inhibiting the ATF6/SREBP-1c pathway Suppresses ER stress and lipogenesis by inhibiting the ATF6/SREBP-1c pathway Reduces lipid accumulation and collagen deposition. Reduces lipid accumulation and collagen deposition. CCl4-induced rat model CCl4-induced rat model Upregulation of cytochrome P450 drug metabolism and PPAR signaling, and downregulation of glutathione metabolism Upregulation of cytochrome P450 drug metabolism and PPAR signaling, and downregulation of glutathione metabolism Alleviates ER stress and apoptosis. Alleviates ER stress and apoptosis. HFHS diet mouse model. HFHS diet mouse model. In vitro HSCs model In vitro HSCs model Attenuates hepatic fibrosis by inhibiting TLR4/NFκB signaling, NLRP3 inflammasome activation Attenuates hepatic fibrosis by inhibiting TLR4/NFκB signaling, NLRP3 inflammasome activation Alleviates ER and oxidative stress. Alleviates ER and oxidative stress. MCD diet-induced mouse model MCD diet-induced mouse model Downregulating ER stress-related genes (GRP78, ATF6), inflammatory markers (TNFα), lipogenic genes (SREBP1c, FAS), and apoptotic pathways (Bax/Bcl2 ratio, caspase3, P53) Downregulating ER stress-related genes (GRP78, ATF6), inflammatory markers (TNFα), lipogenic genes (SREBP1c, FAS), and apoptotic pathways (Bax/Bcl2 ratio, caspase3, P53) Upregulating PPARα, Apo B, and ACAT1 expression. Upregulating PPARα, Apo B, and ACAT1 expression. HF diet + porcine serum mouse model HF diet + porcine serum mouse model Inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammation Inhibiting ER stress response and CHOP/JNK-mediated apoptosis and inflammation Downregulates Coll, α-SMA, TIMP, CHOP, GRP78, and p-JNK expression. Downregulates Coll, α-SMA, TIMP, CHOP, GRP78, and p-JNK expression. CCl4 and BDL mouse models CCl4 and BDL mouse models Promoting Nrf2 nuclear translocation, reducing Nrf2 degradation Promoting Nrf2 nuclear translocation, reducing Nrf2 degradation Inhibiting autophagy and ER stress Inhibiting autophagy and ER stress Increasing SQSTM1 competition to bind KEAP1. Increasing SQSTM1 competition to bind KEAP1. HFHC diet-induced mouse model HFHC diet-induced mouse model Inhibiting hepatic oxidative stress and ER stress response; Inhibiting hepatic oxidative stress and ER stress response; Downregulates GRP78, p-eIF2α, and p-JNK Downregulates GRP78, p-eIF2α, and p-JNK Upregulating ERp57, p-MAPK, and p-AKT. Upregulating ERp57, p-MAPK, and p-AKT. CCl4-induced rat model CCl4-induced rat model In vitro HSC-T6 cells In vitro HSC-T6 cells Interacting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathway Interacting with ASIC1a and inhibiting the ASIC1a-eIF2α-ATF-4 signaling pathway Downregulates ASIC1a, p-eIF2α, ATF-4, VEGF, α-SMA, and Collagen-I. Downregulates ASIC1a, p-eIF2α, ATF-4, VEGF, α-SMA, and Collagen-I. BDL-induced rat model BDL-induced rat model Co-activation of Sirt1/FXR/Nrf2 pathways; upregulates Sirt1, FXR, and Nrf2 Co-activation of Sirt1/FXR/Nrf2 pathways; upregulates Sirt1, FXR, and Nrf2 Downregulates TGF-β1/Smad, HMGB1/TLR4, NF-κB, and STAT1. Downregulates TGF-β1/Smad, HMGB1/TLR4, NF-κB, and STAT1. In vitro LX-2 cells In vitro LX-2 cells Induces ER stress and JNK pathway Induces ER stress and JNK pathway Upregulates CHOP, BIP, caspase-12, p-eIF2α, IRE1α, and JNK Upregulates CHOP, BIP, caspase-12, p-eIF2α, IRE1α, and JNK Downregulates α-SMA and Collagen I, and increases MMPs/TIMPs ratio. Downregulates α-SMA and Collagen I, and increases MMPs/TIMPs ratio. EtOH- and CCl4-induced mouse model EtOH- and CCl4-induced mouse model In vitro HL-7702 and LX-2 cells In vitro HL-7702 and LX-2 cells Downregulates ETBR, PLCβ, CHOP, Bax, cleaved-caspase 12/9/3, α-SMA, and TGF-β1, Downregulates ETBR, PLCβ, CHOP, Bax, cleaved-caspase 12/9/3, α-SMA, and TGF-β1, Upregulates GSH Upregulates GSH Primarily targets ETBR. Primarily targets ETBR. In vitro LX2 cells In vitro LX2 cells CCl4-induced mouse model CCl4-induced mouse model Induces ER stress and apoptosis in HSCs via upregulation of CHOP Induces ER stress and apoptosis in HSCs via upregulation of CHOP Current Research and Future Perspective The compelling preclinical evidence supporting ER stress as a therapeutic target in liver fibrosis has not yet translated into effective clinical treatments. A primary obstacle lies in the suboptimal pharmacokinetic profiles of many promising natural compounds, including poor aqueous solubility, metabolic instability, and, crucially, non-specific biodistribution, which collectively result in low bioavailability and limited efficacy at the target site.118 Therefore, the development of advanced delivery strategies that can enhance the stability of these compounds and direct them precisely to specific liver cell populations is paramount for clinical translation. Nanoparticle-based delivery systems have emerged as a transformative strategy to overcome these pharmacological hurdles.119,120 The core advantage of these systems is their ability to be engineered for cell-specific targeting within the complex liver microenvironment. For instance, targeting hepatocytes can be achieved by functionalizing nanocarriers with galactose or lactose ligands, which are recognized by the asialoglycoprotein receptor highly expressed on hepatocytes.121 This approach allows for the precise delivery of therapeutic agents to alleviate ER stress induced by metabolic insults or viral infections within parenchymal cells. However, the success of anti-fibrotic therapy hinges even more critically on targeting non-parenchymal cells. A well-established strategy exploits the vitamin A storage characteristic of HSCs by using retinol-coupled liposomes or polymeric nanoparticles, which enables the selective delivery of pro-apoptotic or anti-fibrotic agents directly to activated HSCs. Vitamin A-coupled nanoparticles, such as retinol-modified crosslinking nanopolyplexes, hijack retinol-binding protein for precise activated HSC targeting and ROS-responsive siRNA release, effectively reducing collagen deposition and liver injury in preclinical models.122 Furthermore, other targeting ligands, such as those binding to the platelet-derived growth factor receptor β or integrins upregulated on activated HSCs, are under active investigation to achieve high specificity.123,124 Beyond conventional active targeting, the frontier of drug delivery involves biomimetic nanocarriers.125,126 These innovative systems, such as those camouflaged with membranes derived from platelets or even activated HSCs themselves, inherit the complex surface proteins and “self” markers of the source cells. This biomimicry offers unparalleled targeting precision to the fibrotic niche and enhances immune evasion, representing a significant breakthrough for site-specific drug release. Moreover, the development of “smart” nanocarriers, such as the CXCR4-targeted ROS-responsive platform AMD-Dex-ROS-sorafenib, leverages high intracellular ROS levels in activated HSCs for thioketal rupture and on-demand drug release.127 Notwithstanding the promise of advanced delivery systems, several formidable challenges remain. Firstly, the vast majority of evidence is derived from rodent models, creating a critical gap in clinical validation. There is an urgent and unmet need for well-designed Phase I and II clinical trials that rigorously evaluate the safety and efficacy of the most promising candidates, such as curcumin or berberine, in patients with chronic liver diseases.128 Another significant challenge lies in the dualistic nature of the UPR. While inhibiting chronic, maladaptive ER stress is beneficial, uncontrolled suppression can disrupt the UPR’s essential adaptive functions in protein homeostasis. To successfully bridge the translational gap, future research should prioritize several key directions. Advanced human-relevant preclinical models, including patient-derived organoids and 3D-bioprinted liver tissues, will be crucial for better predicting drug efficacy and toxicity before costly clinical trials.129,130 Concurrently, multi-omics technologies such as genomics and proteomics, along with high-throughput screening, will accelerate the discovery of novel natural compounds and precisely define their molecular targets within the complex UPR network.131 Finally, exploring rational combination therapies that synergize ER stress-targeting natural compounds delivered via sophisticated nanocarriers with existing anti-fibrotic agents or first-line treatments like antivirals represents a highly promising strategic direction. In summary, by addressing these challenges through interdisciplinary collaboration integrating pharmacology, nanotechnology, and clinical science, the field can move closer to harnessing the full potential of ER stress modulation as a viable and precise therapeutic strategy for patients with liver fibrosis. Conclusion This review establishes the unequivocal role of ER stress as a central mechanism in the pathogenesis of liver fibrosis, orchestrating a complex interplay of cellular responses in both hepatocytes and HSCs. The extensive catalogue of natural compounds presented herein not only validates ER stress as a druggable target but also offers a rich reservoir of potential therapeutic agents capable of modulating the UPR to halt or reverse fibrogenesis. However, the inherent limitations of these compounds, particularly their pharmacokinetic drawbacks, underscore a critical translational challenge. The advent of sophisticated biomimetic nanotechnologies, exemplified by cell membrane-camouflaged platforms, provides a transformative solution to these obstacles, enabling targeted delivery and maximizing on-site therapeutic efficacy while minimizing off-target effects. Looking forward, the future of anti-fibrotic therapy lies in the convergence of pharmacology, nanotechnology, and precision medicine. Prioritizing the development of intelligent nano-formulations for lead natural compounds, validating their efficacy in human-relevant models, and exploring synergistic combination therapies will be paramount. By harnessing these innovative strategies, the field can successfully translate the compelling preclinical promise of ER stress modulation into tangible clinical benefits for patients suffering from liver fibrosis.